JP2022526914A - 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン - Google Patents

慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン Download PDF

Info

Publication number
JP2022526914A
JP2022526914A JP2021557004A JP2021557004A JP2022526914A JP 2022526914 A JP2022526914 A JP 2022526914A JP 2021557004 A JP2021557004 A JP 2021557004A JP 2021557004 A JP2021557004 A JP 2021557004A JP 2022526914 A JP2022526914 A JP 2022526914A
Authority
JP
Japan
Prior art keywords
canagliflozin
patient
renal
treatment
chronic kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526914A5 (https=
Inventor
アール． ローゼンタール，ノルマン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2022526914A publication Critical patent/JP2022526914A/ja
Publication of JP2022526914A5 publication Critical patent/JP2022526914A5/ja
Priority to JP2025052013A priority Critical patent/JP2025111453A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021557004A 2019-03-26 2020-03-25 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン Pending JP2022526914A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025052013A JP2025111453A (ja) 2019-03-26 2025-03-26 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962823719P 2019-03-26 2019-03-26
US201962823724P 2019-03-26 2019-03-26
US201962823722P 2019-03-26 2019-03-26
US62/823,724 2019-03-26
US62/823,719 2019-03-26
US62/823,722 2019-03-26
US201962835550P 2019-04-18 2019-04-18
US62/835,550 2019-04-18
PCT/EP2020/058415 WO2020193652A1 (en) 2019-03-26 2020-03-25 Canagliflozin for the treatment of diabetic patients with chronic kidney disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025052013A Division JP2025111453A (ja) 2019-03-26 2025-03-26 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン

Publications (2)

Publication Number Publication Date
JP2022526914A true JP2022526914A (ja) 2022-05-27
JP2022526914A5 JP2022526914A5 (https=) 2023-03-10

Family

ID=70050106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557004A Pending JP2022526914A (ja) 2019-03-26 2020-03-25 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン
JP2025052013A Pending JP2025111453A (ja) 2019-03-26 2025-03-26 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025052013A Pending JP2025111453A (ja) 2019-03-26 2025-03-26 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン

Country Status (8)

Country Link
US (1) US20220160739A1 (https=)
EP (1) EP3946367A1 (https=)
JP (2) JP2022526914A (https=)
CN (1) CN113613659A (https=)
CA (1) CA3134786A1 (https=)
MX (1) MX2021011711A (https=)
TW (1) TW202103709A (https=)
WO (1) WO2020193652A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216870A1 (en) * 2021-04-07 2022-10-13 Ur-1 Therapeutics, Inc. Urat1 inhibitor, pharmaceutical compositions and uses thereof
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504649A (ja) * 2014-01-31 2017-02-09 ヤンセン ファーマシューティカ エヌ．ベー． 腎障害及び脂肪性肝障害の治療並びに予防のための方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504649A (ja) * 2014-01-31 2017-02-09 ヤンセン ファーマシューティカ エヌ．ベー． 腎障害及び脂肪性肝障害の治療並びに予防のための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, vol. 138, JPN6024006341, 2018, pages 1537 - 1550, ISSN: 0005650117 *
DIABETES, OBESITY AND METABOLISM, vol. 16, no. 10, JPN6024006342, 2014, pages 1016 - 1027, ISSN: 0005650116 *

Also Published As

Publication number Publication date
JP2025111453A (ja) 2025-07-30
EP3946367A1 (en) 2022-02-09
WO2020193652A1 (en) 2020-10-01
CN113613659A (zh) 2021-11-05
US20220160739A1 (en) 2022-05-26
MX2021011711A (es) 2021-10-22
TW202103709A (zh) 2021-02-01
CA3134786A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
Li–Sheng 2018 Chinese guidelines for prevention and treatment of hypertension—a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension
Baker et al. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension
CN114344293B (zh) 用于治疗猫全身性疾病的血管紧张素ii受体拮抗剂
TW201249432A (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN108685889A (zh) 用于治疗特征为心房增大或重构的疾病的nep抑制剂
JP2025111453A (ja) 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン
JP2016528303A (ja) 新規使用
US20160022632A1 (en) Combination of canagliflozin and probenecid for the treament of hyperuricemia
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
Peters et al. Renal and cardiovascular effects of irbesartan in dialysis patients-a randomized controlled trial protocol (SAFIR study)
EP3784231A1 (en) Methods of treating hypertension
CN103230594A (zh) α-葡萄糖苷酶抑制剂和B族维生素的药物组合物
EP4360631A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
CN101229372A (zh) 一种治疗高血压的药物组合物
HK40062581A (en) Canagliflozin for the treatment of diabetic patients with chronic kidney disease
EA047563B1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
JP2005531492A (ja) 高リスク患者のｉｉ型糖尿病を低減させる方法
Kavanagh Antihypertensive drugs
Kavadi Role of Sotagliflozin in Managing Heart Failure in Diabetes
Steyn SGLT2 inhibitors
TW200403054A (en) Drug composition for prevention or inhibition of advance of diabetic complication
TW201330848A (zh) 治療黑種病人高血壓之方法
EA050266B1 (ru) Фармацевтическая композиция, включающая 1-(3-циано-1-изопропилиндол-5-ил)пиразол-4-карбоновую кислоту
Tablets et al. Pr SANDOZ SAXAGLIPTIN
WO2012011118A2 (en) Development of a fixed dose combination dosage form containing ramipril and carvedilol

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250630